drugset / Trial / NCT04022304
Comparision of Pharmacokinetic and Pharmacodynamic of Biocon Insulin N and Humulin® N
Phase 1
Completed
90 enrolled
Biocon Limited
Profil Institut für Stoffwechselforschung GmbH · collab
RandomizedParallel-groupDouble-blindOther
Summary
Single-centre, randomised, double-blind, three-period, six-sequence, partially replicated design, crossover trial in healthy subjects
Timeline
- Start
- 2019-06-15
- Primary completion
- 2019-12-21
- Completion
- 2019-12-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Biocon Insulin N | Protein / enzyme biologic | 0.4 iu/kg | Subcutaneous |
| Subject | Insulin | Protein / enzyme biologic | 0.4 iu/kg | Subcutaneous |
Indications
No indication recorded.